These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 20234194)

  • 1. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients.
    Calcagno A; Bonora S; Bertucci R; Lucchini A; D'Avolio A; Di Perri G
    AIDS; 2010 Mar; 24(6):931-2. PubMed ID: 20234194
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV-1 RNA levels in the cerebrospinal fluid may increase owing to damage to the blood-brain barrier.
    Burger DM; Boucher CA; Meenhorst PL; Kraayeveld CL; Portegies P; Mulder JW; Hoetelmans RM; Beijnen JH
    Antivir Ther; 1997 Apr; 2(2):113-7. PubMed ID: 11322275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
    Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
    N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation.
    Probasco JC; Deeks SG; Lee E; Hoh R; Hunt PW; Liegler T; Price RW; Spudich SS
    AIDS; 2010 Apr; 24(7):1001-5. PubMed ID: 20299968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
    Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
    Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltegravir with optimized background therapy for resistant HIV-1 infection.
    Steigbigel RT; Cooper DA; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Nguyen BY; Teppler H;
    N Engl J Med; 2008 Jul; 359(4):339-54. PubMed ID: 18650512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal comparison of HIV-1 RNA burden in plasma and cerebrospinal fluid in two patients starting triple combination antiretroviral therapy.
    Iftimovici E; Rabian C; Burgard M; Peytavin G; Rouzioux C; Viard JP
    AIDS; 1998 Mar; 12(5):535-7. PubMed ID: 9543456
    [No Abstract]   [Full Text] [Related]  

  • 9. Viral load in HIV-associated dementia.
    Glass JD; Wesselingh SL
    Ann Neurol; 1998 Jul; 44(1):150-1. PubMed ID: 9667609
    [No Abstract]   [Full Text] [Related]  

  • 10. Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient.
    Fleischbein E; O'Brien J; Martelino R; Fenstersheib M
    AIDS; 2008 Nov; 22(17):2404-5. PubMed ID: 18981785
    [No Abstract]   [Full Text] [Related]  

  • 11. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.
    Yilmaz A; Gisslén M; Spudich S; Lee E; Jayewardene A; Aweeka F; Price RW
    PLoS One; 2009 Sep; 4(9):e6877. PubMed ID: 19721718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir.
    Gisslén M; Norkrans G; Svennerholm B; Hagberg L
    AIDS; 1998 Jan; 12(1):114-6. PubMed ID: 9456264
    [No Abstract]   [Full Text] [Related]  

  • 13. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
    Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
    Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid HIV load in diverse clinical circumstances.
    Jenny-Avital ER; Hoffman J; Katz M; Leider J; Apfelroth S
    Clin Infect Dis; 2008 Jun; 46(12):1938-40; author reply 1940-1. PubMed ID: 18540816
    [No Abstract]   [Full Text] [Related]  

  • 15. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women.
    McKeown DA; Rosenvinge M; Donaghy S; Sharland M; Holt DW; Cormack I; Hay P; Sadiq ST
    AIDS; 2010 Sep; 24(15):2416-8. PubMed ID: 20827058
    [No Abstract]   [Full Text] [Related]  

  • 16. Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy.
    Ellis RJ; Childers ME; Zimmerman JD; Frost SD; Deutsch R; McCutchan JA;
    J Infect Dis; 2003 Jun; 187(11):1818-21. PubMed ID: 12751041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex.
    Gisslen M; Hagberg L; Brew BJ; Cinque P; Price RW; Rosengren L
    J Infect Dis; 2007 Jun; 195(12):1774-8. PubMed ID: 17492593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raltegravir: is a 400 mg once-daily dose enough?
    Lanzafame M; Hill A; Lattuada E; Calcagno A; Bonora S
    J Antimicrob Chemother; 2010 Mar; 65(3):595-7. PubMed ID: 20071368
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-HIV agents. Raltegravir (Isentress)--results after one year.
    TreatmentUpdate; 2007; 19(6):8-9. PubMed ID: 18041152
    [No Abstract]   [Full Text] [Related]  

  • 20. Neurodevelopmental outcomes in children with HIV infection under 3 years of age.
    Foster CJ; Biggs RL; Melvin D; Walters MD; Tudor-Williams G; Lyall EG
    Dev Med Child Neurol; 2006 Aug; 48(8):677-82. PubMed ID: 16836781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.